Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism

Physiology and Behavior

Volumn 104, Issue 4, 2011, Pages 590-598

  Teff, Karen L ^a   Kim, Sangwon F ^b  

^a MONELL CHEMICAL SENSES CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Glucose; Histamine; Insulin; Obesity; Vagus; Weight gain

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; HISTAMINE RECEPTOR; MUSCARINIC RECEPTOR; OLANZAPINE; RISPERIDONE; STEROL REGULATORY ELEMENT BINDING PROTEIN; ZIPRASIDONE;

APPETITE; ARTICLE; CHOLESTEROL BLOOD LEVEL; DOWN REGULATION; ENERGY BALANCE; ENERGY EXPENDITURE; FATTY ACID BLOOD LEVEL; FEEDING BEHAVIOR; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; VAGUS NERVE; WEIGHT CHANGE; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; APPETITE REGULATION; BENZODIAZEPINES; CLOZAPINE; GLUCOSE; HISTAMINE; HISTAMINE ANTAGONISTS; HUMANS; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; OBESITY; RECEPTORS, HISTAMINE; VAGUS NERVE; WEIGHT GAIN;

EID: 79960390191     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2011.05.033     Document Type: Article

References (138)

1. Baptista T., Zarate J., Joober R., Colasante C., Beaulieu S., Paez X., et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004, 5(3):279-299. (Review).
2. Henderson D., Cagliero E., Gray C., Nasrallah R., Hayden D., Schoenfeld D., et al. Clozapine, diabetes mellitus, weight gain, and lipid abnomalities: a five year naturalistic study. Am J Psychiatry 2000, 157:975-981.
3. Newcomer J., Haupt D., Fucetola R., Melson A., Schweiger J., Cooper B., et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002, 59(4):337-345.
4. Lambert M. Olanzapine is associated with more rapid weight gain than haloperidol in people with first episode psychosis. Evid Based Ment Health 2006, 9(3):72.
5. Duncan E., Dunlop B.W., Boshoven W., Woolson S.L., Hamer R.M., Phillips L.S. Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. Int Clin Psychopharmacol 2007, 22(1):1-11.
6. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160(2):290-296.
7. Rettenbacher M.A., Ebenbichler C., Hofer A., Kemmler G., Baumgartner S., Edlinger M., et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol 2006, 21(6):369-372.
8. Hardy T., Marquez E., Kryzhanovskaya L., Taylor C., Cavazzoni P. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol 2006, 26(4):405-408.
9. Huang T.L., Chen J.F. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 2005, 80(1):55-59.
10. Ried LD, Renner BT, McConkey JR, Bengtson MA, Lopez LM. Increased cardiovascular risk with second-generation antipsychotic agent switches. J Am Pharm Assoc (2003) 2006; 46(4):491-498.
11. Wang C.J., Zhang Z.J., Sun J., Zhang X.B., Mou X.D., Zhang X.R., et al. Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics. Biol Psychiatry 2006, 60(12):1309-1313.
12. Nasrallah H.A. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 2006, 11(7 SUPPL.. 7):32-39.
13. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007, 68(SUPPL.. 1):20-27.
14. Eberly L., Prineas R., Cohen J., Vazquez G., Zhi X., Neaton J., et al. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006, 29(1):123-130.
15. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005, 80(1):45-53.
16. Vestri H., Maianu L., Moellering D., Garvey W. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007, 32(4):765-772.
17. Yang L.H., Chen T.M., Yu S.T., Chen Y.H. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 2007, 56(3):202-208.
18. Cope M.B., Nagy T.R., Fernandez J.R., Geary N., Casey D.E., Allison D.B. Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 2005, 29(6):607-614.
19. Oh K.J., Park J., Lee S.Y., Hwang I., Kim J.B., Park T.S., et al. Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. Am J Physiol Endocrinol Metab 2011, 300(4):E624-E632.
20. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302(16):1765-1773.
21. Lipkovich I., Citrome L., Perlis R., Deberdt W., Houston J., Malhotra A.K., et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006, 26(3):316-320.
22. Lieberman D.Z., Goodwin F.K. Use of olanzapine in the treatment of bipolar I disorder. Expert Rev Neurother 2004, 4(5):759-767.
23. Fulton B., Goa K.L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997, 53(2):281-298.
24. Wetterling T., Mussigbrodt H.E. Weight gain: side effect of atypical neuroleptics?. J Clin Psychopharmacol 1999, 19(4):316-321.
25. Melkersson K.I., Hulting A.L., Brismar K.E. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999, 60(11):783-791.
26. Allison D., Mentore J., Heo M., Chandler L., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
27. Meyer J., Nasrallah H., McEvoy J., Goff D., Davis S., Chakos M., et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005, 80:9-18.
28. Parsons B., Allison D.B., Loebel A., Williams K., Giller E., Romano S., et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009, 110(1-3):103-110.
29. Fountaine R.J., Taylor A.E., Mancuso J.P., Greenway F.L., Byerley L.O., Smith S.R., et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring) 2010, 18(8):1646-1651.
30. Blouin M., Tremblay A., Jalbert M.E., Venables H., Bouchard R.H., Roy M.A., et al. Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) 2008, 16(8):1780-1787.
31. Roerig J.L., Mitchell J.E., de Zwaan M., Crosby R.D., Gosnell B.A., Steffem K.J., et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J Clin Psychopharmacol 2005, 25(5):413-418.
32. Kluge M., Schuld A., Himmerich H., Dalal M., Schacht A., Wehmeier P.M., et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol 2007, 27(6):662-666.
33. Case M., Treuer T., Karagianis J., Hoffmann V.P. The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry 2010, 10:72.
34. Stunkard A.J., Messick S. The three factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 1985, 29:71-83.
35. Stauffer V.L., Lipkovich I., Hoffmann V.P., Heinloth A.N., McGregor H.S., Kinon B.J. Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents: a post-hoc analysis. BMC Psychiatry 2009, 9:12.
36. Pouzet B., Mow T., Kreilgaard M., Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 2003, 75(1):133-140.
37. Dwyer D.S., Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003, 75(2):255-260.
38. Zarate J.M., Boksa P., Baptista T., Joober R. Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains. Psychopharmacology (Berl) 2004, 171(2):162-172.
39. Kaur G., Kulkarni S.K. Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26(2):277-285.
40. Coccurello R., Caprioli A., Ghirardi O., Conti R., Ciani B., Daniele S., et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 2006, 186(4):561-571.
41. Davoodi N., Kalinichev M., Korneev S.A., Clifton P.G. Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl) 2009, 203(4):693-702.
42. Cooper G.D., Pickavance L.C., Wilding J.P., Harrold J.A., Halford J.C., Goudie A.J. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 2007, 21(4):405-413.
43. Cooper G.D., Harrold J.A., Halford J.C., Goudie A.J. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(2):428-436.
44. van der Zwaal E.M., Luijendijk M.C., Adan R.A., La Fleur S.E. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 2008, 585(1):130-136.
45. Ashim S., Warrington S., Anderson I.M. Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications. J Psychopharmacol 2004, 18(1):128-132.
46. Nasrallah H.A., Newcomer J.W. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004, 24(5 SUPPL.. 1):S7-S14.
47. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004, 37(1):1-11.
48. Melkersson K., Dahl M.L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004, 64(7):701-723.
49. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010, 123(2-3):225-233.
50. L'Italien G.J., Casey D.E., Kan H.J., Carson W.H., Marcus R.N. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007, 68(10):1510-1516.
51. Scheen A.J., De Hert M.A. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007, 33(3):169-175.
52. van Winkel R., De Hert M., Wampers M., Van Eyck D., Hanssens L., Scheen A., et al. Major changes in glucose metabolism, including new-onset diabetes, within 3months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008, 69(3):472-479.
53. Wu R.R., Zhao J.P., Liu Z.N., Zhai J.G., Guo X.F., Guo W.B., et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006, 186(4):572-578.
54. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160(2):290-296.
55. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008, 101(1-3):266-272.
56. Newcomer J. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004, 65(SUPPL.. 18):36-46.
57. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160(2):290-296.
58. Ebenbichler C., Laimer M., Eder U., Mangweth B., Weiss E., Hofer A., et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003, 64(12):1436-1439.
59. Henderson D., Cagliero E., Copeland P., Borba C., Evins E., Hayden D., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005, 62(1):19-28.
60. Haupt D.W., Fahnestock P.A., Flavin K.A., Schweiger J.A., Stevens A., Hessler M.J., et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007, 32(12):2561-2569.
61. van Nimwegen L.J., Storosum J.G., Blumer R.M., Allick G., Venema H.W., de Haan L., et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008, 93(2):572-577.
62. Kinon B., Basson B., Gilmore J., Tollefson G. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001, 62(2):92-100.
63. Baptista T., Kin N.M.K.N.Y., Beaulieu S., De Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002, 35:205-219.
64. Sowell M., Mukhopadhyay N., Cavazzoni P., Shankar S., Steinberg H., Breier A., et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002, 87(6):2918-2923.
65. Sowell M., Mukhopadhyay N., Cavazzoni P., Carlson C., Mudaliar S., Chinnapongse S., et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003, 88(12):5875-5880.
66. Hardy T.A., Meyers A.L., Yu J., Shankar S.S., Steinberg H.O., Porksen N.K., Porksen N.K. Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2weeks. Diabetes Care 2007, 30(1):157-158.
67. Sacher J., Mossaheb N., Spindelegger C., Klein N., Geiss-Granadia T., Sauermann R., et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008, 33(7):1633-1641.
68. Vidarsdottir S., de Leeuw van Weenen J.E., Frolich M., Roelfsema F., Romijn J.A., Pijl H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 2010, 95(1):118-125.
69. Chiu C., Chen K., Liu H., Lu M.L. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006, 26(5):504-507.
70. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1year. J Clin Psychiatry 2002, 63(5):425-433.
71. Koro C.E., Meyer J.M. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol 2005, 6(3):148-157.
72. Kaddurah-Daouk R., McEvoy J., Baillie R.A., Lee D., Yao J.K., Doraiswamy P.M., et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007, 12(10):934-945.
73. Vik-Mo A.O., Birkenaes A.B., Ferno J., Jonsdottir H., Andreassen O.A., Steen V.M. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 2008, 11(5):679-684.
74. Robinson K., Yacoub S., Buse M. At therapeutic concentrations, olanzapine does not affect basal or insulin-stimulated glucose transport in 3T3-L1 adipocytes. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:93-98.
75. Chintoh A.F., Mann S.W., Lam L., Lam C., Cohn T.A., Fletcher P.J., et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008, 28(5):494-499.
76. Houseknecht K., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H. Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2006, 1-29. Online.
77. Chintoh A.F., Mann S.W., Lam T.K., Giacca A., Remington G. Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophr Res 2008, 104(1-3):23-30.
78. Albaugh V.L., Vary T.C., Ilkayeva O., Wenner B.R., Maresca K.P., Joyal J.L., et al. Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophr Bull 2010, May 21. [Epub ahead of print].
79. Martins P.J., Haas M., Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 2010, 59(10):2418-2425.
80. Markowitz J., Brown C., Moore T. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999, 33(1):73-85. (Review).
81. Kroeze W., Hufeisen S., Popadak B., Renock S., Steinberg S., Ernsberger P., et al. HI-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
82. Bymaster F., Felder C., Tzavara E., Nomikos G., Calligaro D., Mckinzie D. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(7):1125-1143. (Review).
83. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13(1):27-35.
84. Kim S.F., Huang A.S., Snowman A.M., Teuscher C., Snyder S.H. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007, 104(9):3456-3459.
85. Starrenburg F.C., Bogers J.P. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry 2009, 24(3):164-170.
86. Stahl S.M., Mignon L., Meyer J.M. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr Scand 2009, 119(3):171-179.
87. Gao Q., Horvath T.L. Neurobiology of feeding and energy expenditure. Annu Rev Neurosci 2007, 30:367-398.
88. Wynne K., Stanley S., McGowan B., Bloom S. Appetite control. J Endocrinol 2005, 184(2):291-318.
89. Sandoval D., Cota D., Seeley R.J. The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation. Annu Rev Physiol 2008, 70:513-535.
90. Berthoud H.R., Morrison C. The brain, appetite, and obesity. Annu Rev Psychol 2008, 59:55-92.
91. Lutter M., Nestler E.J. Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr 2009, 139(3):629-632.
92. Hommel J.D., Trinko R., Sears R.M., Georgescu D., Liu Z.W., Gao X.B., et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 2006, 51(6):801-810.
93. Macht M., Mueller J. Immediate effects of chocolate on experimentally induced mood states. Appetite 2007, 49(3):667-674.
94. Pandit R., de Jong J.W., Vanderschuren L.J., Adan R.A. Neurobiology of overeating and obesity: the role of melanocortins and beyond. Eur J Pharmacol 2011, 660(1):28-42.
95. Nirenberg M.J., Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006, 21(4):524-529.
96. Dagher A., Robbins T.W. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009, 61(4):502-510.
97. Cornelius J.R., Tippmann-Peikert M., Slocumb N.L., Frerichs C.F., Silber M.H. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010, 33(1):81-87.
98. Cannon C.M., Palmiter R.D. Reward without dopamine. J Neurosci 2003, 23(34):10827-10831.
99. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the nervous system. Physiol Rev 2008, 88(3):1183-1241.
100. Martinez-Mir M.I., Pollard H., Moreau J., Arrang J.M., Ruat M., Traiffort E., et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 1990, 526(2):322-327.
101. Nguyen T., Shapiro D.A., George S.R., Setola V., Lee D.K., Cheng R., et al. Discovery of a novel member of the histamine receptor family. Mol Pharmacol 2001, 59(3):427-433.
102. Panula P., Yang H.Y., Costa E. Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci U S A 1984, 81(8):2572-2576.
103. Brabant C., Alleva L., Quertemont E., Tirelli E. Involvement of the brain histaminergic system in addiction and addiction-related behaviors: a comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence. Prog Neurobiol 2010, 92(3):421-441.
104. Yoshimatsu H. Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm. Nutrition 2008, 24(9):827-831.
105. Lecklin A., Etu-Seppala P., Stark H., Tuomisto L. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Brain Res 1998, 793(1-2):279-288.
106. Masaki T., Chiba S., Yasuda T., Noguchi H., Kakuma T., Watanabe T., et al. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004, 53(9):2250-2260.
107. Orthen-Gambill N. Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol Biochem Behav 1988, 31(1):81-86.
108. Sakata T., Ookuma K., Fukagawa K., Fujimoto K., Yoshimatsu H., Shiraishi T., et al. Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res 1988, 441(1-2):403-407.
109. Masaki T., Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol Sci 2006, 27(5):279-284.
110. Tsuda K., Yoshimatsu H., Niijima A., Chiba S., Okeda T., Sakata T. Hypothalamic histamine neurons activate lipolysis in rat adipose tissue. Exp Biol Med (Maywood) 2002, 227(3):208-213.
111. Masaki T., Yoshimatsu H., Chiba S., Watanabe T., Sakata T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 2001, 50(2):376-384.
112. Zawalich W.S., Zawalich K.C., Rasmussen H. Cholinergic agonists prime the B-cell to glucose stimulation. Endocrinology 1989, 125:2400-2406.
113. Zawalich W.S., Zawalich K.C., Shulman G.I., Rossetti L. Chronic in vivo hyperglycemia impairs phosphoinositide hydrolysis and insulin release in isolated perfused rat islets. Endocrinology 1990, 126:253-260.
114. Zawalich W., Zawalich K., Kelley G. Time-dependent effects of cholinergic stimulation on beta cell responsiveness. Pflugers Arch 1996, 432(4):589-596.
115. Doliba N.M., Qin W., Vatamaniuk M.Z., Buettger C.W., Collins H.W., Magnuson M.A., et al. Cholinergic regulation of fuel-induced hormone secretion and respiration of SUR1-/- mouse islets. Am J Physiol Endocrinol Metab 2006, 291(3):E525-E535.
116. Doliba N.M., Qin W., Vatamaniuk M.Z., Li C., Zelent D., Najafi H., et al. Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine. Am J Physiol Endocrinol Metab 2004, 286(5):E834-E843.
117. Doliba N.M., Qin W., Vinogradov S.A., Wilson D.F., Matschinsky F.M. Palmitic acid acutely inhibits acetylcholine- but not GLP-1-stimulated insulin secretion in mouse pancreatic islets. Am J Physiol Endocrinol Metab 2010, 299(3):E475-E485.
118. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005, 54(5):1552-1558.
119. Teff K.L., Mattes R.D., Engelman K. Cephalic phase insulin release in normal weight males: verification and reliability. Am J Physiol 1991, 261(24):E430-E436.
120. Teff K.L. Cephalic phase insulin release in humans: mechanism and function. Appetite and body weight regulation: sugar, fat and macronutrient substitutes 1994, 37-50. CRC Press, Boca Raton. J.D. Fernstrom, G.D. Miller (Eds.).
121. Teff K.L., Engelman K. Oral sensory stimulation improves glucose tolerance: effects on post-prandial glucose, insulin, C-peptide and glucagon. Am J Physiol 1996, 270:R1371-R1379.
122. Teff K.L., Townsend R.R. Prolonged mild hyperglycemia induces vagally mediated compensatory increase in C-peptide secretion in humans. J Clin Endocrinol Metab 2004, 89:5606-5613.
123. Henderson J.R., Jeffreys D.B., Jones R.H., Stanley D. The effect of atropine on the insulin release caused by oral and intravenous glucose in human subjects. Acta Endocrinol 1976, 83:772-780.
124. Shimazu T. Regulation of glycogen metabolism in liver by the autonomic nervous system vs activation of glycogen synthetase by vagal stimulation. Biochim Biophys Acta 1971, 252:28-38.
125. Shimazu T. Glycogen synthetase activity in liver: regulation by the autonomic nerves. Science 1967, 156:1256-1257.
126. Shiota M., Jackson P., Galassetti P., Scott M., Neal D.W., Cherrington A.D. Combined intraportal infusion of acetylcholine and adrenergic blockers augments net hepatic glucose uptake. Am J Physiol Endocrinol Metab 2000, 278(3):E544-E552.
127. Stumpel F., Jungermann K. Sensing by intrahepatic muscarinic nerves of a portal-arterial glucose concentration gradient as a signal for insulin-dependent glucose uptake in the perfused rat liver. FEBS Lett 1997, 406:119-122.
128. Chap Z., Ishida T., Chou J., Lewis R., Hartley C., et al. Effects of atropine and gastric inhibitory polypeptide on hepatic glucose uptake and insulin extraction in conscious dogs. J Clin Invest 1985, 76:1174-1181.
129. Pocai A., Obici S., Schwartz G.J., Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab 2005, 1:53-61.
130. Boyle J.G., Liggett S.B., Shah S.D., Cryer P.E. Direct muscarinic cholinergic inhibition of hepatic glucose production in humans. J Clin Invest 1988, 82:445-449.
131. Teff K.L., Rickels M.R., Grudziak J., Rickels K. Short-term administration of olanzapine induces insulin resistance in healthy subjects, independent of weight gain. Endocr Rev 2010, 31(3):S2541.
132. Vidarsdottir S., Roelfsema F., Streefland T., Holst J.J., Rehfeld J.F., Pijl H. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur J Endocrinol 2010, 162(1):75-83.
133. Hommel J.D., Trinko R., Sears R.M., Georgescu D., Liu Z.W., Gao X.B., et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 2006, 51(6):801-810.
134. Davis C., Patte K., Levitan R., Reid C., Tweed S., Curtis C. From motivation to behaviour: a model of reward sensitivity, overeating, and food preferences in the risk profile for obesity. Appetite 2007, 48(1):12-19.
135. Figlewicz D.P. Adiposity signals and food reward: expanding the CNS roles of insulin and leptin. Am J Physiol 2003, 284(4):R882-R892.
136. Blundell J. Serotonin and appetite. Neuropharmacology 1984, 23(12B):1537-1551.
137. Carrub M., Mantegazza P., Memo M., Missale C., Spano P. Peripheral and central mechanisms of action of serotoninergic anorectic drugs. Appetite 1986, 7:105-113.
138. Piji H., Koppeschaar H., Willekens F., Veldhuia H., Meinders A. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 1991, 15:237-242.